Loading
A phase 3 trial testing Rondecabtagene autoleucel in diffuse large B-cell lymphoma and hodgkin lymphoma, now recruiting.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy is a phase 3 interventional study registered as NCT07188558, led by Lyell Immunopharma, and recruiting on the registry. Official title: A Phase 3 Randomised Controlled Trial of Rondecabtagene Autoleucel, an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting. Planned enrolment is 400 participants (estimated). The study started in 2026-01-12 and primary completion is expected in 2029-12. No results have been posted on ClinicalTrials.gov.